Skip to Content

ECCO 2019: The use of first-line biologics in patients with Crohn’s disease in Norway

Karoline Anisdahl, Oslo University Hospital, Norway, and her colleagues aimed to assess whether there was a change over time in the proportion of patients receiving biologics between 2011 and 2016 and if the preferred first-line biologic changed after the introduction of biosimilar infliximab.

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top